Our Foundation and Background

At ESSA, we develop cutting-edge oncology therapeutics and advance science to better understand cancer biology. Our focus is based on developing novel and proprietary therapies to augment patient options and expand currently approved treatments.

 

2008

Drs. Sadar and Andersen discover a family of AR N-terminal domain-selective inhibitors referred to as the EPI compound family.


2009

ESSA founded in Vancouver, British Columbia, Canada.


2010 – 2013

EPI-506 is identified as a clinical drug candidate.


2014

ESSA awarded $12 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT) and opens office in Houston, Texas.


2015

ESSA becomes a public company actively traded on both the Toronto Stock Exchange (EPI) and the NASDAQ stock exchange (EPIX).

ESSA receives FDA and Health Canada approvals to start EPI-506 clinical program; first patient dosed in the EPI-506 Phase 1/2 clinical study.


2016

EPI-506 Phase 1/2 trial is enrolling.